Assistant Professor, Molecular Medicine, Case Western Reserve University School of Medicine
Hematology
Dr. Ramon V. Tiu, MD
|
|
Give Review
Ramon V. Tiu, MD works in the field of Hematology. He received 1 awards: "CMS Meaningful Use Stage 1 Certification". Ramon is also a published doctor. He has 69 paper published. The most recent paper is: Impact of vancomycin-resistant enterococcal bacteremia on outcome during acute myeloid leukemia induction therapy. He accepts Medicare payments and is registered with Medicare.gov.
Publications
- Impact of vancomycin-resistant enterococcal bacteremia on outcome during Acute myeloid leukemia induction therapy.
- Cyclosporine dependent pure red Cell aplasia: A case presentation.
- Regulation of Stat5 by FAK and PAK1 in Oncogenic FLT3- and KIT-Driven Leukemogenesis.
- Screening for SF3B1 mutations is a useful tool to differentiate between acquired clonal and non-clonal sideroblastic Anemia.
- Practical management of patients with chronic myeloid Leukemia who develop tyrosine kinase inhibitor-resistant BCR-ABL1 mutations.
- Familial systemic Mastocytosis with germline KIT K509I mutation is sensitive to treatment with imatinib, dasatinib and PKC412.
- Ruxolitinib leads to improvement of pulmonary hypertension in patients with myelofibrosis.
- Spontaneous recovery of severe nilotinib-induced bone marrow aplasia and successful retreatment with dasatinib in a patient with Chronic Phase Chronic Myeloid Leukemia.
- Clinicopathologic and molecular characterization of Myeloid neoplasms harboring isochromosome 17(q10).
- Distinct iron architecture in SF3B1 mutant myelodysplastic Syndromes patients is linked to an SLC25A37 splice variant with a retained intron.
- Atypical chronic myeloid Leukemia (aCML) BCR-ABL1-negative is clinicopathologically distinct from unclassifiable myelodysplastic/myeloproliferative neoplasms (MDS/MPN-...
- Successful use of very low dose subcutaneous decitabine to treat high-risk myelofibrosis with Sweet Syndrome that was refractory to 5-azacitidine.
- Molecular genetics of myelofibrosis and its associated Disease phenotypes.
- Molecular pathogenesis of myelodysplastic Syndromes.
- Making sense of the myelodysplastic/myeloproliferative neoplasms overlap Syndromes.
- Sex differences in the incidence of chronic myeloid Leukemia.
- Predictive Factors for Latency Period and a Prognostic Model for Survival in Patients with Therapy-related AML.
- Epidemiology and risk factors for infections in myelodysplastic Syndromes.
- Impact of molecular mutations on treatment response to DNMT inhibitors in myelodysplasia and related neoplasms.
- Outcomes in obese and overweight Acute myeloid leukemia patients receiving chemotherapy dosed according to actual body weight.
- The need for additional genetic markers for myelodysplastic Syndrome stratification: what does the future hold for prognostication?
- Spliceosomal gene mutations are frequent events in the diverse mutational spectrum of chronic myelomonocytic Leukemia but largely absent in juvenile myelomonocytic leu...
- Phase 2 study of the lenalidomide and azacitidine combination in patients with higher-risk myelodysplastic Syndromes.
- Expression of phosphorylated signal transducer and activator of transcription 5 is associated with an increased risk of death in Acute myeloid leukemia.
- SF3B1 haploinsufficiency leads to formation of ring sideroblasts in myelodysplastic Syndromes.
- Single Nucleotide Polymorphism Array Lesions, TET2, DNMT3A, ASXL1 and CBL Mutations Are Present in Systemic Mastocytosis.
- Targeted therapy for patients with chronic myeloid Leukemia: clinical trial experience and challenges in inter-trial comparisons.
- Immunomodulatory agents in myelofibrosis.
- A phase 2 trial of combination therapy with thalidomide, arsenic trioxide, dexamethasone, and ascorbic acid (TADA) in patients with overlap Myelodysplastic/myeloprolif...
- De Novo polycythaemia vera arising 5???years following Acute myeloid leukemia remission: suggestion of a chemotherapy resistant JAK2 clone.
- Blood consult: treating del(5q) myelodysplastic Syndromes.
- Rho Kinase Regulates the Survival and Transformation of Cells Bearing Oncogenic Forms of KIT, FLT3, and BCR-ABL.
- Mutational spectrum analysis of chronic myelomonocytic Leukemia includes genes associated with epigenetic regulation: UTX, EZH2 and DNMT3A.
- Lenalidomide in del 5q MDS: Responses and side effects revisited.
- Updates in Cytogenetics and Molecular Markers in MDS.
- Efficacy of rabbit anti-thymocyte globulin in severe aplastic Anemia.
- SNP array-based karyotyping: differences and similarities between aplastic Anemia and hypocellular myelodysplastic syndromes.
- Prognostic impact of SNP array karyotyping in myelodysplastic Syndromes and related myeloid malignancies.
- Optimization of therapy for severe aplastic Anemia based on clinical, biologic, and treatment response parameters: conclusions of an international working group on sev...
- Clonal evolution in aplastic Anemia.
- Characterization of chromosome arm 20q abnormalities in Myeloid malignancies using genome-wide single nucleotide polymorphism array analysis.
- New lesions detected by single nucleotide polymorphism array-based chromosomal analysis have important clinical impact in Acute myeloid leukemia.
- Loss of heterozygosity 4q24 and TET2 mutations associated with Myelodysplastic/myeloproliferative neoplasms.
- Tumor lysis Syndrome.
- Ibutilide to expedite ED therapy for recent-onset atrial fibrillation flutter.
- Mutated calreticulin retains structurally disordered C terminus that cannot bind Ca(2+): some mechanistic and therapeutic implications.
- Novel homo- and hemizygous mutations in EZH2 in Myeloid malignancies.
- Clofarabine for myelodysplastic Syndromes.
- Concomitant conjunctival mucosa-associated lymphoid tissue Lymphoma and small lymphocytic Lymphoma associated with immunoglobulin M macroglobulinemia successfully trea...
- Application of array-based whole genome scanning technologies as a cytogenetic tool in haematological malignancies.
- Base excision repair dysfunction in a subgroup of patients with myelodysplastic Syndrome.
- The role of AMG-531 in the treatment of thrombocytopenia in idiopathic thrombocytopenic purpura and myelodysplastic Syndromes.
- Time to post-remission therapy is an independent prognostic factor in adults with Acute lymphoblastic leukemia.
- Myelodysplastic Syndromes with del(5q): indications and strategies for cytogenetic testing.
- Detection of cryptic chromosomal lesions including acquired segmental uniparental disomy in advanced and low-risk myelodysplastic Syndromes.
- Chromosomal lesions and uniparental disomy detected by SNP arrays in MDS, MDS/MPD, and MDS-derived AML.
- Immune pathogenesis of paroxysmal nocturnal hemoglobinuria.
- High-resolution genomic arrays facilitate detection of novel cryptic chromosomal lesions in myelodysplastic Syndromes.
- Immune-mediated bone marrow failure Syndromes of progenitor and stem cells: molecular analysis of cytotoxic T cell clones.
- Epsilon aminocaproic acid reduces transfusion requirements in patients with Thrombocytopenic hemorrhage.
- Refractory Anemia with ringed sideroblasts associated with marked thrombocytosis (RARS-T), another myeloproliferative condition characterized by JAK2 V617F mutation.
- Recurrent ischemic stroke in Paroxysmal nocturnal hemoglobinuria: Paroxysmal nocturnal hemoglobinuria or missed patent foramen ovale?
- A Phase 1 study of imatinib mesylate in combination with cytarabine and daunorubicin for c-kit positive relapsed Acute myeloid leukemia.
- Mutations of e3 ubiquitin ligase cbl family members constitute a novel common pathogenic lesion in Myeloid malignancies.
- p53-Independent, Normal Stem Cell Sparing Epigenetic Differentiation Therapy for Myeloid and Other Malignancies.
- TP53 mutations in Myeloid malignancies are either homozygous or hemizygous due to copy number-neutral loss of heterozygosity or deletion of 17p.
- Single nucleotide polymorphism arrays complement metaphase cytogenetics in detection of new chromosomal lesions in MDS.
- Clonality of the stem cell compartment during evolution of myelodysplastic Syndromes and other bone marrow failure Syndromes.
Conditions Treated
- Acute Leukemia
- Anemia
- Antiphospholipid Syndrome (APS)
- Chronic Myeloid Leukemia (CML)
- View All
Doctors Specialties
- Hematology
- Medical Oncology
- Oncology
Accepted Insurances
Awards
- CMS Meaningful Use Stage 1 Certification
Education
-
Cleveland Clinic Foundation -
University of Santo Tomas
Hospital
-
Cleveland Clinic
Drug Facts
| NPI NUMBER | 1457435414 | |
| NPPES Provider LastName | TIU | |
| NPPES Provider FirstName | RAMON | |
| NPPES Provider ZIPCode | 441950001 | |
| NPPES Provider State | OH | |
| Specialty Description | Hematology | |
| Total Claim Count | 463.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1457435414 |
| Last Name Of The Provider | TIU |
| First Name Of The Provider | RAMON |
| View All |
Similar Doctors
|
|
Dr. Holleh D. Husseinzadeh, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Waqas Rehman, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Hamed Daw, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Anita Schwandt, MD |
|
Dr. Jane A. Little, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Cortney V. Jones, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Brian T. Hill, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Rania Rayes, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Susan McInnes, MD |
|
|
Dr. Poornanand Palaparty, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Cindylou F. Connell, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Leland L. Metheny III, MD |
|
|
Dr. Bo Zhao, MD |